ArticleJournal of thoracic disease2025
Pulsed electric field ablation safety and characterization near sensitive structures in lung: a preclinical and clinical case series study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Pulsed Electric Field Ablation Reprograms Tumor Immunity and Stimulates Germinal Center Formation in Tertiary Lymphoid Structures in Patients with Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Safety and Efficacy of Bronchoscopic Pulsed Electric Field Ablation for Lung Cancer and Metastases.JTO clinical and research reports · 2026Article
- See and Strike: A Dual-Force Paradigm for Real-Time Lung Cancer Diagnosis and Non-Thermal Ablation.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- The role of pulsed electric field therapy in non-small cell lung cancer: a narrative review of a novel minimally invasive intervention.Journal of thoracic disease · 2026Review
- Six-Month Local Control Rates and Immune Responses After Pulsed Electric Field Ablation in Metastatic Cancer.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Since pulsed electric fields (PEFs) can ablate tissue without reliance on ionizing radiation or thermal processes, there is potential for this technique to safely ablate near sensitive structures in the lung in a way that may be distinct from thermal or radiative technologies. The purpose of this study is to demonstrate the ability of Aliya PEFs to be delivered safely in the lungs near critical structures via percutaneous and bronchoscopic access. Methods: This study evaluates performance of the Aliya PEF system in healthy swine lung tissue when specifically delivered near sensitive structures (pleura, diaphragm, large vessels and airways). Clinically, six human subjects who received PEF near similar structures are also presented. These six patients all underwent the Aliya PEF procedure because they presented with lesions adjacent to sensitive structures that were not considered candidates for traditional ablative modalities. Twelve pigs received lung ablations percutaneously (n=6) or endobronchially (n=6). Animals were followed for 3-5 days or 28 days with routine computed tomography and gross and histopathology. Results: There were no intraprocedural concerns in any of the animals, including no incidences of electrocardiogram disturbances. Gross pathology and histology confirm the onset of cell death with retained extracellular matrix integrity without clinically significant alteration of sensitive structures despite intentional device placement near (1-5 mm) these structures. There were no in-life or pathology-based safety or performance concerns and no adverse events during the treatment procedures associated with the use of Aliya System. Clinically, all the patients who received PEF tolerated the procedure well and without significant adverse sequelae. Conclusions: This PEF technology can kill cells while sparing the extracellular matrix and reducing damage to sensitive structures. This study demonstrates that the Aliya PEF may afford a safer alternative to other ablation modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.